Bokebayev Zh, Kukiyev I, Shulgau Z, Gulyayev A, Draganov K
JSC "Astana Medical University", Astana; RSE "National Center for Biotechnology" under the Science Committee of Ministry of Education and Science of the Republic of Kazakhstan. Astana, Kazakhstan; «Tokuda Hospital Sofia», Republic of Bulgaria.
JSC "Astana Medical University", Astana; RSE "National Center for Biotechnology".
Georgian Med News. 2018 Mar(276):177-182.
The aim of the study was to evaluate the wound healing properties of the recombinant human angiogenin drug in the gel form on the models of planar musculocutaneous wound and a linear wound. The rats were divided into 3 groups: 1st group - control animals, that did not get any treatment of wounds; 2nd group - experimental, where animals' wound surface was treated with recombinant human angiogenin in a gel medicinal form; and the 3rd group - a comparison group, where animals were treated with "Solcoseryl" drug. The resulted morphology data and the time of complete epithelialization of planar wounds suggest that the human angiogenin drug in gel form has a pronounced wound healing activity. The latter surpasses the studied parameters of the reference drug "Solcoseryl", by contributing to the acceleration of healing process of planar musculocutaneous and linear wounds in rats.
本研究的目的是在平面肌皮伤口和线性伤口模型上评估凝胶形式的重组人血管生成素药物的伤口愈合特性。将大鼠分为3组：第1组为对照动物，未对伤口进行任何处理；第2组为实验组，用凝胶药物形式的重组人血管生成素处理动物的伤口表面；第3组为比较组，用“舒康博”药物处理动物。平面伤口的形态学数据和完全上皮化时间表明，凝胶形式的人血管生成素药物具有显著的伤口愈合活性。通过促进大鼠平面肌皮伤口和线性伤口的愈合过程，其在伤口愈合活性上超过了参比药物“舒康博”的研究参数。
